Syneos Health, Inc. (NASDAQ:SYNH) Receives $54.22 Average Target Price from Analysts

Syneos Health, Inc. (NASDAQ:SYNHGet Rating) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $54.22.

A number of research firms have recently weighed in on SYNH. Evercore ISI reduced their target price on shares of Syneos Health to $73.00 in a research report on Tuesday, August 9th. Robert W. Baird dropped their price target on Syneos Health from $80.00 to $42.00 and set an “outperform” rating on the stock in a research report on Monday, November 7th. William Blair lowered Syneos Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 3rd. Guggenheim downgraded Syneos Health from a “buy” rating to a “neutral” rating in a report on Wednesday, September 14th. Finally, Citigroup reduced their price target on Syneos Health from $55.00 to $30.00 and set a “neutral” rating for the company in a report on Sunday, November 6th.

Syneos Health Price Performance

Shares of SYNH stock opened at $32.63 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.84. The stock has a market cap of $3.36 billion, a price-to-earnings ratio of 11.87 and a beta of 1.75. The business’s fifty day moving average is $45.46 and its 200 day moving average is $60.99. Syneos Health has a twelve month low of $22.89 and a twelve month high of $104.17.

Hedge Funds Weigh In On Syneos Health

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Syneos Health by 16.3% during the first quarter. BlackRock Inc. now owns 11,527,780 shares of the company’s stock worth $933,174,000 after acquiring an additional 1,617,330 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Syneos Health by 33.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 2,868,800 shares of the company’s stock valued at $232,229,000 after purchasing an additional 723,812 shares in the last quarter. Cooke & Bieler LP grew its holdings in Syneos Health by 39.1% during the 1st quarter. Cooke & Bieler LP now owns 2,359,503 shares of the company’s stock worth $191,002,000 after acquiring an additional 663,152 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Syneos Health during the second quarter worth $46,487,000. Finally, Macquarie Group Ltd. lifted its position in Syneos Health by 69.9% during the third quarter. Macquarie Group Ltd. now owns 1,151,572 shares of the company’s stock valued at $54,351,000 after acquiring an additional 473,794 shares during the last quarter. 94.80% of the stock is owned by institutional investors.

About Syneos Health

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Read More

Analyst Recommendations for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.